CardiologyOnline.net

Cardiology Xagena

Search results for "Brilinta"

The presentation of the PLATO ( A Study of Platelet Inhibition and Patient Outcomes ), showed that Ticagrelor ( Brilinta ) reduced the rate of cardiovascular events ( cardiovascular death, myocardial ...


American Heart Association ( AHA ) and American College of Cardiology ( ACC ) have updated the guideline for the management of patients with non–ST-elevation acute coronary syndromes ( NSTE-ACS ). T ...


The results of the phase IV ATLANTIC study, which indicates that the profile of Ticagrelor ( Brilinta, Brilique ) is comparable whether administered in a pre-hospital or in-hospital setting to ST segm ...


The results of a sub-analysis of the PEGASUS-TIMI 54 study, which evaluated reasons and rates for discontinuation of Ticagrelor ( Brilinta, Brilique ) in patients with a history of myocardial infarcti ...


The potential benefit of dual antiplatelet therapy beyond 1 year after a myocardial infarction has not been established. Researchers have investigated the efficacy and safety of Ticagrelor ( Brili ...


A sub-analysis of the PEGASUS-TIMI 54 study, assessing the effect of Ticagrelor ( Brilinta, Brilique ) in reducing atherothrombotic events in post-myocardial infarction patients, based on the time fro ...


Ticagrelor ( Brilinta, Brilique ) administered in the ambulance reduces ischaemic events 24 hours after primary percutaneous coronary intervention ( PCI ), according to findings from the ATLANTIC-H24 ...